
Peptides for weight loss — what holds up beyond the GLP-1s
Peptides for weight loss range from FDA-approved medications to compounds that fell short in human trials or are still being tested. Here is what holds up for semaglutide, tirzepatide, tesamorelin, AOD-9604, and retatrutide, how to judge a claim, and where any of them fits alongside the basics.
The ads are hard to miss. A peptide that “targets belly fat.” A growth-hormone fragment that “burns fat without touching your appetite.” An investigational compound sold as stronger than anything your doctor can prescribe, shipped with a mixing chart and no questions asked. Meanwhile GLP-1 medications have become household names, and the word “peptide” has stretched to cover all of it.
That stretch causes real confusion. “Peptide” is a chemistry word for a short chain of amino acids and nothing more. Insulin is a peptide. So are semaglutide and tirzepatide. So is an unregulated powder bought online.
The compounds people ask about, honestly
Online peptide protocols are a separate question, covered in peptides aren’t a fad.
- Semaglutide and tirzepatide. FDA-approved prescription medications, and by far the best studied of anything here. Both are engineered versions of gut hormones — GLP-1, and for tirzepatide GIP as well — that slow stomach emptying and quiet hunger through receptors in the brain. Their side effects are mostly digestive, and both labels warn about pancreatitis, gallbladder disease, and kidney injury from dehydration. Choosing between them is covered in semaglutide or tirzepatide.
- Tesamorelin. A lab-made analog of growth-hormone-releasing hormone, the hypothalamic signal that cues the pituitary to release growth hormone. It is FDA-approved for one purpose: reducing excess abdominal fat in adults with HIV-associated lipodystrophy. It reduces deep visceral fat without much change in overall weight, and its label says it is not indicated for weight-loss management. It can raise blood sugar and cause fluid retention — swelling, joint pain, or carpal tunnel symptoms — and the visceral fat tends to return once it is stopped. Any other use is off-label.
- AOD-9604. A modified fragment of the growth-hormone molecule, designed to keep growth hormone’s fat-releasing effect without its effects on growth or blood sugar. It looked promising in early studies, but in its largest and longest human trial it did not produce meaningful weight loss over placebo, and its development as an obesity drug was dropped. It is not FDA-approved.
- Retatrutide. An investigational “triple agonist” acting on GLP-1, GIP, and glucagon receptors. Glucagon is best known for raising blood sugar, but acting on its receptor also increases energy expenditure and fat burning in the liver, while the GLP-1 and GIP actions hold blood sugar in check. At the time of writing it remains in clinical trials and is not FDA-approved; its long-term safety and who it suits are still being worked out. The FDA has warned companies selling it online under a “for research purposes” label.
These are often sold side by side as if they were interchangeable. They are not.
“Peptide” tells you what a molecule is made of. It does not tell you whether it works, whether it is safe, or what is actually in the vial.
What fat loss actually depends on
Every compound above acts on hormone systems that already govern body fat. Insulin is the body’s main storage signal. After a meal it moves glucose into muscle and liver and tells fat cells to hold on to what they have. In insulin resistance, muscle, liver, and fat respond less to that signal, and the pancreas compensates by making more insulin. Visceral fat compounds the problem: it is more metabolically active, keeps shedding fatty acids and inflammatory signals straight toward the liver even when insulin is high, and deepens the insulin resistance that fed it.
Growth hormone pushes the other way. It mobilizes stored fat, visceral fat in particular. But it also opposes insulin’s action on blood sugar, so anything that raises growth hormone can push glucose and A1c up — the wrong direction for someone whose problem began with insulin. That is why IGF-1, the liver’s response to growth hormone, gets checked alongside glucose markers whenever this axis is involved.
Skeletal muscle is the body’s largest site of insulin-driven glucose uptake, which makes it a main buffer against high blood sugar and high insulin. That buffer is what a steep cut in eating puts at risk, on a GLP-1 or off one: without enough protein and resistance training, more of the weight lost is muscle, and the body’s capacity to clear sugar shrinks with it. And sleep sits underneath everything: the largest pulse of growth hormone comes in deep sleep, and short sleep makes cells less responsive to insulin and raises evening cortisol.
Chinese medicine describes the same terrain differently. The heavy, tired, bloated picture that often travels with insulin resistance reads as Spleen Qi deficiency with Dampness — Qi here meaning the body’s capacity to do its work, in this case turning food into usable energy, and Dampness what collects when that work falls short. A constant, driven appetite with signs of heat reads as Stomach Heat instead. Either way, the pattern is treated through how you eat, move, and sleep, with acupuncture and herbal formulas as support.
How to judge a claim
Whatever the compound, the same questions separate a reasonable option from a sales pitch:
- Approval status. Is it FDA-approved, and for what? An approval covers a specific use in a specific group of people, and a compound that is only in clinical trials is not approved for any use.
- Human evidence. Cell and animal studies are where a compound starts, not where it proves itself; plenty of molecules that shrink fat in mice do nothing useful in people. Has it been tested in humans, against placebo, for the outcome you care about?
- Sourcing and purity. Is it prescribed by a licensed clinician and filled by a state-licensed pharmacy, or sold online as a research chemical? A vial sold as a “research” peptide carries no assurance of identity, potency, sterility, or freedom from bacterial endotoxin, and a certificate of analysis from the seller does not change that.
- Medical supervision. Someone qualified should take your history, screen for who should not use a compound, and follow you as things change. A personal or family history of medullary thyroid carcinoma or MEN2 rules out semaglutide and tirzepatide, active cancer is a firm stop for anything that raises growth hormone, and none of these compounds is used in pregnancy.
- Labs. A baseline and a follow-up: fasting glucose and insulin, A1c, a lipid panel, liver and kidney function, a full thyroid panel, and IGF-1 when the growth-hormone axis is involved. Without numbers before and after, no one can say whether something worked or caused harm.
Red flags in peptide marketing
Online peptide sales lean on a recognizable set of moves. Be wary of:
- No evaluation before you buy. A checkout page in place of a medical history, a screen for who should not take it, and labs.
- Borrowed credibility. A brand-name drug’s results used to sell a different compound, or an approval for one condition presented as an approval for weight loss.
- Promised numbers. Before-and-after photos presented as typical, and a set amount of loss promised by a set date. Bodies do not follow a script, and careful clinicians do not promise one.
- No downsides listed. Every compound with a real effect has side effects and people who should not use it. A page that names none is an advertisement, not information.
Where any of this fits
Two things come before any medication. One is the foundation: protein at each meal, resistance training, enough sleep, and work on blood sugar and insulin through what and when you eat. It shapes how much of what comes off is fat rather than muscle, and how well the result holds. The other is a full evaluation, so a decision about medication rests on your physiology rather than an ad. If a medication is warranted, the ones FDA-approved for weight management come first. Anything beyond them is weighed case by case, never as a default or a shortcut past those two steps.
How we approach it
Bring everything you take to the first consultation, in its original packaging: prescriptions, supplements, and anything bought online. The label tells us more than a product name does. We go through how your weight has changed, what you have tried, and how you sleep and handle stress. Baseline labs follow, so we are collecting all the pieces of the puzzle before anything is added. If a medication fits, a licensed prescribing clinician writes the prescription; we coordinate with them and judge the result by follow-up labs as well as the scale.
We don’t mask symptoms — we look to address the underlying issues that cause symptoms and dis-ease. You can read about our functional medicine approach, or contact us with questions before you book.
Disclosure: AOD-9604 and retatrutide exist as RUO (research use only), are not FDA-approved, and are for self research use only. Semaglutide, tirzepatide, and tesamorelin are FDA-approved as brand-name prescription medications (such as Wegovy, Zepbound, and Egrifta) that require a medical evaluation and ongoing supervision; compounded versions and products sold as research peptides are not FDA-approved. Tesamorelin’s approval is limited to reducing excess abdominal fat in adults with HIV-associated lipodystrophy.
The journal is written by Dr. Nazzar from the practice. Articles reflect clinical observation and current research, not personalized medical advice. To explore your own case, schedule a consultation.
